Full text is available at the source.
Abstract
An estimation of population-level eligibility for GLP-1RA medications among adults in Australia was conducted.
- The study focused on adults with overweight or obesity.
- Eligibility was assessed based on approved indications for chronic weight management.
- Secondary prevention of cardiovascular disease was also considered in the eligibility criteria.
- The findings may inform healthcare providers about potential patient populations for GLP-1RA treatments.
Simplified